Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.49 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.49 |
| ▸ | BRD2 | P25440 | 3/20 | 0.49 |
| ▸ | BRD7 | Q9NPI1 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33533254 | 0.95 | BRD9 (0.49) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL33533083 | 0.91 | BRD9 (0.51) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL23783302 | 0.86 | BRD4 (0.49) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL33532825 | 0.84 | BRD9 (0.48) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL33533012 | 0.84 | BRD9 (0.54) | BRD9BRD7CYP3A4 | |
| SCHEMBL33530765 | 0.84 | BRD9 (0.49) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL23783038 | 0.83 | BRD4 (0.53) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL33531804 | 0.83 | BRD9 (0.48) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL33532700 | 0.83 | BRD9 (0.48) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL30297131 | 0.83 | BRD4 (0.51) | BRD4BRD9BRD2BRD7CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | BRD4 161/4885BRD9 3/4885BRD2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.